McMurray JJV, Solomon SD, Inzucchi SE, et al. - In this phase 3, placebo-controlled trial, experts randomized 4,744 individuals with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin or placebo, in addition to recommended therapy in order to ascertain the impacts of sodium-glucose cotransporter 2 inhibitors in individuals with established heart failure and a decreased ejection fraction, irrespective of the presence or absence of T2DM. Data from results suggested that among individuals with heart failure and a decreased ejection fraction, despite the presence or absence of diabetes, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin compared with those among those who received a placebo.